Transport
Franciscan Health Crown Point
Franciscan Health Crown Point was paid $11.34M by Medicaid between Jan 2018 and Dec 2024, across 93 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH CROWN POINT
CROWN POINT, IN 46307
CROWN POINT, IN 46307
33aNPI1336205798assigned 12/29/2006
33bProvider typeAmbulance
28Total paid$11.34M
24GClaims207,583
24DCodes billed93
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Indiana
Rank by total paid#2 of 85
Median peer was paid$457K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,132 | $472K | |
| 2019 | 17,983 | $1.02M | |
| 2020 | 16,224 | $1.12M | |
| 2021 | 29,716 | $1.86M | |
| 2022 | 46,591 | $2.69M | |
| 2023 | 46,339 | $2.57M | |
| 2024incomplete | 28,598 | $1.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 21,521 | 18,784 | $3.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 18,951 | 15,769 | $2.74M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.8% | 9,770 | 8,014 | $654K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5.7% | 9,236 | 8,196 | $642K |
| 71045 | Radiologic examination, chest; single view | 5.1% | 4,617 | 3,716 | $577K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 4,272 | 3,445 | $534K |
| 71046 | Radiologic examination, chest; 2 views | 4.1% | 3,241 | 2,764 | $463K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 4,274 | 3,992 | $316K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 3,410 | 2,944 | $258K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 1,502 | 1,344 | $253K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 4,456 | 3,731 | $180K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.6% | 4,383 | 3,379 | $178K |
81 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 2,244 | $140K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 308 | $126K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 3,550 | $126K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 5,427 | $125K |
| 80053 | Comprehensive metabolic panel | 1.0% | 16,496 | $114K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,414 | $108K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 682 | $64K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,417 | $59K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,479 | $56K |
| 87634 | <1% | 942 | $53K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 488 | $43K |
| 84484 | <1% | 5,302 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,381 | $33K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 261 | $32K |
| 59025 | Fetal non-stress test | <1% | 105 | $30K |
| 81025 | <1% | 5,145 | $28K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 510 | $25K |
| A0425 | Ground mileage, per statute mile | <1% | 625 | $24K |
| 83735 | <1% | 4,410 | $21K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 29 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,330 | $17K |
| 83690 | <1% | 4,037 | $17K | |
| 81001 | <1% | 6,176 | $13K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 419 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 254 | $12K |
| 87631 | <1% | 117 | $11K | |
| 80050 | General health panel | <1% | 69 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 441 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,799 | $8K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 27 | $8K |
| 99218 | <1% | 58 | $8K | |
| 80061 | Lipid panel | <1% | 810 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 251 | $7K |
| 82607 | <1% | 389 | $5K | |
| 85730 | <1% | 1,111 | $5K | |
| 85610 | <1% | 1,186 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 191 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $3K |
| 80076 | <1% | 543 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 85 | $3K |
| 71250 | <1% | 20 | $3K | |
| 82746 | <1% | 222 | $3K | |
| 84207 | <1% | 116 | $3K | |
| 81003 | <1% | 1,555 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 99 | $3K |
| 82077 | <1% | 218 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 208 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 37 | $1K |
| 82728 | <1% | 102 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 36 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 222 | $1K |
| 83880 | <1% | 33 | $913.39 | |
| 84145 | <1% | 41 | $728.20 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 33 | $719.12 |
| 87486 | <1% | 27 | $712.06 | |
| 87581 | <1% | 27 | $712.06 | |
| 85379 | <1% | 90 | $703.97 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 36 | $695.52 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $641.88 |
| 83540 | <1% | 104 | $611.08 | |
| 87430 | <1% | 99 | $575.56 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 58 | $567.02 |
| 84439 | <1% | 78 | $537.59 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $442.21 |
| 87420 | <1% | 68 | $339.42 | |
| 84703 | <1% | 47 | $253.81 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 19 | $201.88 |
| 87040 | <1% | 22 | $123.84 | |
| 81002 | <1% | 96 | $98.12 | |
| 85027 | <1% | 17 | $85.66 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,798 | $39.59 |
| 87081 | <1% | 25 | $24.04 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 20 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 34 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 14 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 141 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 431 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 139 | $0.00 |
| 94726 | 0% | 13 | $0.00 | |
| 94729 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKATS, JUSTIN (DIVISION CFO)